Odronextamab Reference: HY-P99038 Odronextamab is a hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody that binds CD3 on T cells and CD20 on B cells.
Inflammation Antibody Panel Reference: ARG30323 Inflammation antibody; NFkB p65 phospho (Ser536) antibody; COX2 antibody; iNOS antibody; beta Actin antibody
Secukinumab Reference: HY-P9927 Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.
Neuroinflammation Antibody Panel Reference: ARG30324 Neuroinflammation antibody; CD68 antibody; AIF1 / Iba 1 antibody; GFAP antibody
Nesvacumab Reference: HY-P99036 Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1.
Inflammatory Cell Antibody Panel Reference: ARG30325 Inflammatory Cell antibody; MPO / Myeloperoxidase antibody; CD3 antibody; CD20 antibody; CD68 antibody
Tiragolumab Reference: HY-P9986 Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab, may be effective against multiple solid malignancies-most notably non-small cell lung cancer.
Inflammatory Cell Antibody Panel (for mouse) Reference: ARG30326 Inflammatory Cell antibody; Ly6G + Ly6C antibody; EMR1 F4/80 antibody; CD3 antibody; CD45R / B220 antibody
Rosopatamab Reference: HY-P99239 Rosopatamab (HJ 591) is a humanised anti-PSMA monoclonal antibody that can be used in cancer research, particularly in prostate cancer.
Microvascular Density Antibody Panel Reference: ARG30327 Microvascular Density antibody; CD31 antibody; Desmin antibody; Ki-67 antibody; alpha smooth muscle Actin antibody
Cendakimab Reference: HY-P99496 Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).